pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
PFIZER · news · pharmadog
← back to PFIZER
News mentioning PFIZER
392
stories
Jun 4, 26
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
stat
Jun 4, 26
STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
stat
Jun 3, 26
House bill aims to crack down on China biotech deals
biopharma dive
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
Jun 2, 26
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
biopharma dive
Jun 2, 26
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
biopharma dive
Jun 2, 26
STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
stat
Jun 1, 26
STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
stat
Jun 1, 26
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
stat
Jun 1, 26
2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?
biopharma dive
May 31, 26
STAT+: A standing ovation for RevMed, and caution for Akeso
stat
May 31, 26
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
stat
May 31, 26
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
stat
May 31, 26
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
stat
May 31, 26
STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
stat
May 30, 26
STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
stat
May 29, 26
STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
stat
May 29, 26
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
stat
May 29, 26
STAT+: Allogene CEO David Chang stepping down
stat
May 29, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
May 29, 26
Pfizer, Innovent strike $10B cancer drug deal
biopharma dive
May 29, 26
Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs
endpoints
May 15, 26
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
biopharma dive
May 14, 26
AstraZeneca follows Merck with Phase 3 win in bladder cancer
endpoints
May 12, 26
STAT+: Hims’ sales miss as telehealth competition grows
stat
May 12, 26
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
biopharma dive
May 12, 26
Pfizer and Arvinas give disappointing breast cancer drug to Rigel
endpoints
May 12, 26
GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
onclive
May 12, 26
A year after Vertex’s big launch, pain drug research faces a pivotal moment
biopharma dive
May 8, 26
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
onclive
← prev
page 12 of 14
next →